---
document_datetime: 2023-12-15 16:41:34
document_pages: 4
document_pathfilename: www.ema.europa.eu/en/documents/procedural-steps-after/ruxience-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
document_name: ruxience-epar-procedural-steps-taken-scientific-information-after-authorisation-archive_en.pdf
version: success
processing_time: 2.6507829
conversion_datetime: 2025-12-24 15:47:07.843658
docling_version:
  docling-serve: 1.9.0
  docling-jobkit: 1.8.0
  docling: 2.66.0
  docling-core: 2.57.0
  docling-ibm-models: 3.10.3
  docling-parse: 4.7.2
  python: cpython-313 (3.13.11)
  plaform: macOS-26.2-arm64-arm-64bit-Mach-O
---
## Ruxience

Procedural steps taken and scientific information after the authorisation

| Application number   | Scope                                                                                                                      | Opinion/ Notification 1 issued on   | Commission Decision Issued 2 / amended on   | Product Information affected 3   | Summary                                                                                                                |
|----------------------|----------------------------------------------------------------------------------------------------------------------------|-------------------------------------|---------------------------------------------|----------------------------------|------------------------------------------------------------------------------------------------------------------------|
| IAIN/0014            | A.5.a - Administrative change - Change in the name and/or address of a manufacturer/importer responsible for batch release | 14/12/2023                          |                                             | Annex II and PL                  |                                                                                                                        |
| PSUSA/2652/ 202211   | Periodic Safety Update EU Single assessment - rituximab                                                                    | 22/06/2023                          | 23/08/2023                                  |                                  | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for |

<!-- image -->

<!-- image -->

<div style=\"page-break-after: always\"></div>

|                    |                                                                                                                                                                                                                                                              |            |            |             | PSUSA/2652/202211.                                                                                                                                                                                                                                 |
|--------------------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|-------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| IA/0012            | A.6 - Administrative change - Change in ATC Code/ATC Vet Code                                                                                                                                                                                                | 12/12/2022 | 23/08/2023 | SmPC        |                                                                                                                                                                                                                                                    |
| II/0011            | B.I.a.1.e - Change in the manufacturer of AS or of a starting material/reagent/intermediate for AS - The change relates to a biological AS or a starting material [-] used in the manufacture of a biological/immunological product                          | 01/09/2022 | 23/08/2023 | Annex II    | The section A in Annex II (Manufacturers of the biological active substance and manufacturers responsible for batch release) has been updated as follows: Pfizer Ireland Pharmaceuticals Grange Castle Business Park Clondalkin, Dublin 22 Ireland |
| PSUSA/2652/ 202111 | Periodic Safety Update EU Single assessment - rituximab                                                                                                                                                                                                      | 23/06/2022 | 24/08/2022 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s) for PSUSA/2652/202111.                                                                                                           |
| IB/0009            | C.I.11.z - Introduction of, or change(s) to, the obligations and conditions of a marketing authorisation, including the RMP - Other variation                                                                                                                | 07/01/2022 | n/a        |             |                                                                                                                                                                                                                                                    |
| IB/0008            | C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 23/09/2021 | 24/08/2022 | SmPC and PL |                                                                                                                                                                                                                                                    |
| PSUSA/2652/ 202011 | Periodic Safety Update EU Single assessment - rituximab                                                                                                                                                                                                      | 24/06/2021 | 20/08/2021 | SmPC and PL | Refer to Scientific conclusions and grounds recommending the variation to terms of the Marketing Authorisation(s)' for PSUSA/2652/202011.                                                                                                          |
| IB/0007            | C.I.2.a - Change in the SPC, Labelling or PL of a                                                                                                                                                                                                            | 15/04/2021 | 20/08/2021 | PL          |                                                                                                                                                                                                                                                    |

<div style=\"page-break-after: always\"></div>

|           | generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                |            |            |                        |
|-----------|-------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------|------------|------------------------|
| IB/0004   | B.II.f.1.b.3 - Stability of FP - Extension of the shelf life of the finished product - After dilution or reconstitution (supported by real time data)                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                     | 30/07/2020 | 20/08/2021 | SmPC                   |
| IB/0003/G | This was an application for a group of variations. C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH C.I.2.a - Change in the SPC, Labelling or PL of a generic/hybrid/biosimilar products following assessment of the same change for the reference product - Implementation of change(s) for which NO new additional data is required to be submitted by the MAH | 08/07/2020 | 31/07/2020 | SmPC, Labelling and PL |

<div style=\"page-break-after: always\"></div>

| II/0001   | to extend the validated hold times of the virus retaining filtration (VRF) load and the ultrafiltration/diafiltration (UF/DF) load during active substance manufacture. B.I.a.2.c - Changes in the manufacturing process of the AS - The change refers to a [-] substance in the manufacture of a biological/immunological substance which may have a significant impact on the medicinal and is not related to a protocol   | 25/06/2020   | n/a   | product   |
|-----------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|--------------|-------|-----------|
| IA/0002   | B.II.e.3.a - Change in test procedure for the immediate packaging of the finished product - Minor changes to an approved test procedure                                                                                                                                                                                                                                                                                      | 29/05/2020   | n/a   |           |